ACET
Adicet Bio, Inc.
Price Chart
Latest Quote
$7.98
Current Price| Previous Close | $7.99 |
| Open | $7.90 |
| Day High | $8.13 |
| Day Low | $7.81 |
| Volume | 106,959 |
Stock Information
| Shares Outstanding | 9.60M |
| Total Debt | $15.54M |
| Cash Equivalents | $103.10M |
| Net Income | $-115.01M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $76.61M |
| EPS (TTM) | $-20.00 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 16/42| Debt to Equity | 0.09 |
| Debt to Earnings | -0.15 |
| Current Ratio | 9.29 |
| Quick Ratio | 9.09 |
| Avg Revenue Growth | -25.00% |
| Return on Equity | -62.76% |
| Avg FCF Growth | 11.47% |
| FCF Yield | -122.04% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $7.98 | 106,959 |
| 2026-01-30 | $7.99 | 170,800 |
| 2026-01-29 | $8.50 | 50,800 |
| 2026-01-28 | $8.45 | 74,400 |
| 2026-01-27 | $8.54 | 122,200 |
| 2026-01-26 | $8.70 | 134,600 |
| 2026-01-23 | $8.44 | 110,800 |
| 2026-01-22 | $8.40 | 242,700 |
| 2026-01-21 | $8.07 | 248,500 |
| 2026-01-20 | $7.90 | 308,400 |
| 2026-01-16 | $8.28 | 137,900 |
| 2026-01-15 | $7.94 | 113,100 |
| 2026-01-14 | $8.29 | 92,900 |
| 2026-01-13 | $8.29 | 112,700 |
| 2026-01-12 | $7.81 | 190,100 |
| 2026-01-09 | $8.03 | 149,700 |
| 2026-01-08 | $8.09 | 170,500 |
| 2026-01-07 | $8.45 | 116,900 |
| 2026-01-06 | $8.05 | 163,900 |
| 2026-01-05 | $8.15 | 282,500 |
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
đ° Latest News
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Zacks âĸ 2025-10-07T13:40:02Z
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-09-30T16:00:03Z
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Zacks âĸ 2025-08-12T16:00:03Z
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
Insider Monkey âĸ 2025-08-11T13:46:17Z
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001
Clinical Trials Arena âĸ 2025-07-25T11:27:53Z
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Simply Wall St. âĸ 2025-04-27T13:31:14Z
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts
Insider Monkey âĸ 2025-03-23T12:43:57Z
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001
Investing.com âĸ 2025-02-27T13:36:28ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $24,990,000 | $9,730,000 |
| Operating Revenue | $0 | $0 | $24,990,000 | $9,730,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $4,000 | $25,000 | $80,000 | $176,000 |
| Total Expenses | $127,615,000 | $132,576,000 | $97,541,000 | $71,163,000 |
| Other Income Expense | $-217,000 | $-20,035,000 | $-919,000 | $-606,000 |
| Other Non Operating Income Expenses | $-217,000 | $-573,000 | $-919,000 | $-606,000 |
| Net Non Operating Interest Income Expense | $10,710,000 | $9,953,000 | $3,680,000 | $-85,000 |
| Interest Expense Non Operating | $4,000 | $25,000 | $80,000 | $176,000 |
| Operating Expense | $127,615,000 | $132,576,000 | $97,541,000 | $71,163,000 |
| General And Administrative Expense | $28,292,000 | $26,533,000 | $26,295,000 | $22,220,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Net Interest Income | $10,710,000 | $9,953,000 | $3,680,000 | $-85,000 |
| Interest Income | $10,714,000 | $9,978,000 | $3,760,000 | $91,000 |
| Normalized Income | $-117,122,000 | $-123,196,000 | $-69,790,000 | $-61,999,000 |
| Net Income From Continuing And Discontinued Operation | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Total Operating Income As Reported | $-127,615,000 | $-152,038,000 | $-72,551,000 | $-61,433,000 |
| Net Income Common Stockholders | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Net Income | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Net Income Including Noncontrolling Interests | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Net Income Continuous Operations | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Pretax Income | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-62,124,000 |
| Special Income Charges | $0 | $-19,462,000 | $0 | - |
| Interest Income Non Operating | $10,714,000 | $9,978,000 | $3,760,000 | $91,000 |
| Operating Income | $-127,615,000 | $-132,576,000 | $-72,551,000 | $-61,433,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-21.28 | $-52.96 | $-27.20 | $-32.00 |
| Basic EPS | $-21.28 | $-52.96 | $-27.20 | $-32.00 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-110,650,000 | $-117,073,000 | $-67,135,000 | $-60,410,000 |
| Total Unusual Items | $0 | $-19,462,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-19,462,000 | $0 | - |
| Reconciled Depreciation | $6,468,000 | $6,098,000 | $2,575,000 | $1,538,000 |
| EBITDA (Bullshit earnings) | $-110,650,000 | $-136,535,000 | $-67,135,000 | $-60,410,000 |
| EBIT | $-117,118,000 | $-142,633,000 | $-69,710,000 | $-61,948,000 |
| Diluted Average Shares | $5,491,652 | $2,690,150 | $2,567,517 | $1,934,509 |
| Basic Average Shares | $5,491,652 | $2,690,150 | $2,567,517 | $1,934,509 |
| Diluted NI Availto Com Stockholders | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Tax Provision | $0 | $0 | $0 | $-125,000 |
| Impairment Of Capital Assets | $0 | $19,462,000 | $0 | - |
| Research And Development | $99,323,000 | $106,043,000 | $71,246,000 | $48,943,000 |
| Selling General And Administration | $28,292,000 | $26,533,000 | $26,295,000 | $22,220,000 |
| Other Gand A | $28,292,000 | $26,533,000 | $26,295,000 | $22,220,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $186,609,000 | $170,175,000 | $272,876,000 | $283,667,000 |
| Total Assets | $220,219,000 | $207,295,000 | $330,690,000 | $338,938,000 |
| Total Non Current Assets | $40,083,000 | $45,023,000 | $69,652,000 | $56,500,000 |
| Other Non Current Assets | $3,331,000 | $822,000 | $1,211,000 | $2,037,000 |
| Current Assets | $180,136,000 | $162,272,000 | $261,038,000 | $282,438,000 |
| Other Current Assets | $474,000 | $457,000 | $336,000 | $2,000 |
| Prepaid Assets | $3,359,000 | $2,104,000 | $2,611,000 | $4,678,000 |
| Cash Cash Equivalents And Short Term Investments | $176,303,000 | $159,711,000 | $257,656,000 | $277,544,000 |
| Cash And Cash Equivalents | $56,495,000 | $159,711,000 | $257,656,000 | $277,544,000 |
| Goodwill And Other Intangible Assets | - | $0 | $19,462,000 | $19,462,000 |
| Receivables | - | $0 | $435,000 | $214,000 |
| Accrued Interest Receivable | - | $0 | $435,000 | $29,000 |
| Accounts Receivable | - | - | $0 | $185,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Taxes Receivable | - | - | - | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $17,234,000 | $20,924,000 | $21,023,000 | $20,944,000 |
| Long Term Debt And Capital Lease Obligation | $14,102,000 | $17,703,000 | $18,531,000 | $19,377,000 |
| Current Debt And Capital Lease Obligation | $3,132,000 | $3,221,000 | $2,492,000 | $1,567,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $33,610,000 | $37,120,000 | $38,352,000 | $35,809,000 |
| Total Non Current Liabilities Net Minority Interest | $14,218,000 | $17,833,000 | $18,645,000 | $19,492,000 |
| Other Non Current Liabilities | $116,000 | $130,000 | $114,000 | $115,000 |
| Current Liabilities | $19,392,000 | $19,287,000 | $19,707,000 | $16,317,000 |
| Payables And Accrued Expenses | $9,148,000 | $9,552,000 | $11,512,000 | $5,925,000 |
| Payables | $4,830,000 | $2,625,000 | $4,404,000 | $3,263,000 |
| Accounts Payable | $4,830,000 | $2,625,000 | $4,404,000 | $3,263,000 |
| Current Deferred Liabilities | - | - | $0 | $4,805,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Taxes Liabilities | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $186,609,000 | $170,175,000 | $292,338,000 | $303,129,000 |
| Total Equity Gross Minority Interest | $186,609,000 | $170,175,000 | $292,338,000 | $303,129,000 |
| Stockholders Equity | $186,609,000 | $170,175,000 | $292,338,000 | $303,129,000 |
| Gains Losses Not Affecting Retained Earnings | $16,000 | $0 | $0 | $0 |
| Other Equity Adjustments | $16,000 | - | - | - |
| Retained Earnings | $-497,894,000 | $-380,772,000 | $-238,114,000 | $-168,324,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $5,160,573 | $2,704,399 | $2,684,676 | $2,483,557 |
| Share Issued | $5,160,573 | $2,704,399 | $2,684,676 | $2,483,557 |
| Tangible Book Value | $186,609,000 | $170,175,000 | $272,876,000 | $283,667,000 |
| Invested Capital | $186,609,000 | $170,175,000 | $292,338,000 | $303,129,000 |
| Working Capital | $160,744,000 | $142,985,000 | $241,331,000 | $266,121,000 |
| Capital Lease Obligations | $17,234,000 | $20,924,000 | $21,023,000 | $20,944,000 |
| Total Capitalization | $186,609,000 | $170,175,000 | $292,338,000 | $303,129,000 |
| Additional Paid In Capital | $684,479,000 | $550,943,000 | $530,448,000 | $471,449,000 |
| Capital Stock | $8,000 | $4,000 | $4,000 | $4,000 |
| Common Stock | $8,000 | $4,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $14,102,000 | $17,703,000 | $18,531,000 | $19,377,000 |
| Current Capital Lease Obligation | $3,132,000 | $3,221,000 | $2,492,000 | $1,567,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,112,000 | $6,514,000 | $5,703,000 | $4,020,000 |
| Current Accrued Expenses | $4,318,000 | $6,927,000 | $7,108,000 | $2,662,000 |
| Net PPE | $36,752,000 | $44,201,000 | $48,979,000 | $35,001,000 |
| Accumulated Depreciation | $-21,315,000 | $-14,847,000 | $-8,753,000 | $-6,326,000 |
| Gross PPE | $58,067,000 | $59,048,000 | $57,732,000 | $41,327,000 |
| Leases | $28,228,000 | $26,643,000 | $19,959,000 | $1,614,000 |
| Construction In Progress | $198,000 | $265,000 | $9,292,000 | $13,014,000 |
| Other Properties | $28,087,000 | $30,589,000 | $27,772,000 | $25,860,000 |
| Machinery Furniture Equipment | $1,554,000 | $1,551,000 | $709,000 | $839,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $119,808,000 | $0 | - | $0 |
| Goodwill | - | $0 | $19,462,000 | $19,462,000 |
| Current Deferred Revenue | - | - | $0 | $4,805,000 |
| Investments And Advances | - | - | - | $0 |
| Held To Maturity Securities | - | - | - | $0 |
| Buildings And Improvements | - | - | - | $20,358,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-93,496,000 | $-98,181,000 | $-61,547,000 | $-64,098,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-92,378,000 | $-93,717,000 | $-44,765,000 | $-51,052,000 |
| Cash Flow From Continuing Operating Activities | $-92,378,000 | $-93,717,000 | $-44,765,000 | $-51,052,000 |
| Operating Gains Losses | - | $-4,000 | $54,000 | $31,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,118,000 | $-4,464,000 | $-16,782,000 | $-13,046,000 |
| Investing Cash Flow | $-119,242,000 | $-4,464,000 | $-16,782,000 | $-2,796,000 |
| Cash Flow From Continuing Investing Activities | $-119,242,000 | $-4,464,000 | $-16,782,000 | $-2,796,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $110,918,000 | $0 | $43,360,000 | $238,129,000 |
| Financing Cash Flow | $111,307,000 | $236,000 | $41,509,000 | $242,685,000 |
| Cash Flow From Continuing Financing Activities | $111,307,000 | $236,000 | $41,509,000 | $242,685,000 |
| Net Other Financing Charges | $-141,000 | $-150,000 | $-3,598,000 | $-261,000 |
| Net Common Stock Issuance | $110,918,000 | $0 | $43,360,000 | $238,129,000 |
| Common Stock Issuance | $110,918,000 | $0 | $43,360,000 | $238,129,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $59,398,000 | $159,711,000 | $257,656,000 | $277,694,000 |
| Beginning Cash Position | $159,711,000 | $257,656,000 | $277,694,000 | $88,857,000 |
| Changes In Cash | $-100,313,000 | $-97,945,000 | $-20,038,000 | $188,837,000 |
| Proceeds From Stock Option Exercised | $530,000 | $386,000 | $1,747,000 | $4,817,000 |
| Net Investment Purchase And Sale | $-118,124,000 | $0 | $0 | $10,250,000 |
| Sale Of Investment | $11,000,000 | $0 | $0 | $10,250,000 |
| Purchase Of Investment | $-129,124,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-1,118,000 | $-4,464,000 | $-16,782,000 | $-13,046,000 |
| Purchase Of PPE | $-1,118,000 | $-4,464,000 | $-16,782,000 | $-13,046,000 |
| Change In Working Capital | $-5,525,000 | $252,000 | $2,744,000 | $-6,057,000 |
| Change In Other Current Liabilities | $-3,691,000 | $-99,000 | $-2,264,000 | $-511,000 |
| Change In Other Current Assets | $353,000 | $358,000 | $929,000 | $42,000 |
| Change In Payables And Accrued Expense | $-916,000 | $-933,000 | $7,541,000 | $1,983,000 |
| Change In Accrued Expense | $-2,022,000 | $750,000 | $5,831,000 | $846,000 |
| Change In Payable | $1,106,000 | $-1,683,000 | $1,710,000 | $1,137,000 |
| Change In Account Payable | $1,106,000 | $-1,683,000 | $1,710,000 | $1,137,000 |
| Change In Prepaid Assets | $-1,271,000 | $926,000 | $1,343,000 | $1,634,000 |
| Other Non Cash Items | $3,236,000 | $2,874,000 | $2,526,000 | $1,724,000 |
| Stock Based Compensation | $22,233,000 | $20,259,000 | $17,126,000 | $12,511,000 |
| Asset Impairment Charge | $0 | $19,462,000 | $0 | $1,190,000 |
| Amortization Of Securities | $-1,668,000 | $0 | $0 | $10,000 |
| Depreciation Amortization Depletion | $6,468,000 | $6,098,000 | $2,575,000 | $1,538,000 |
| Depreciation And Amortization | $6,468,000 | $6,098,000 | $2,575,000 | $1,538,000 |
| Gain Loss On Sale Of PPE | $0 | $-4,000 | $54,000 | $31,000 |
| Net Income From Continuing Operations | $-117,122,000 | $-142,658,000 | $-69,790,000 | $-61,999,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $43,000 |
| Change In Other Working Capital | - | - | $-4,805,000 | $-9,175,000 |
| Change In Receivables | - | - | $185,000 | $-30,000 |
| Changes In Account Receivables | - | - | $185,000 | $-30,000 |